Published in Gut on August 01, 2002
Medullary thymic epithelial cell depletion leads to autoimmune hepatitis. J Clin Invest (2013) 1.57
Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci (2011) 1.50
Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol (2008) 1.34
Autoantibody-negative autoimmune hepatitis. Dig Dis Sci (2011) 1.03
Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis (2004) 0.94
Autoimmune hepatitis--approach to diagnosis. MedGenMed (2006) 0.92
Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol (2010) 0.90
Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci (2012) 0.89
Prevalence of autoimmune liver disease related autoantibodies in Chinese patients with primary biliary cirrhosis. Dig Dis Sci (2011) 0.87
The overlap syndromes of autoimmune hepatitis. Dig Dis Sci (2012) 0.86
Development of a recombinant cell-based indirect immunofluorescence assay for the determination of autoantibodies against soluble liver antigen in autoimmune hepatitis. Clin Dev Immunol (2013) 0.85
Antibodies to soluble liver antigen and alpha-enolase in patients with autoimmune hepatitis. J Autoimmune Dis (2004) 0.84
Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig Dis Sci (2003) 0.84
Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. World J Gastroenterol (2015) 0.81
Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol (2009) 0.81
Challenges in the diagnosis and management of autoimmune hepatitis. Can J Gastroenterol (2013) 0.79
Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis. Auto Immun Highlights (2013) 0.78
Characterization of human gene encoding SLA/LP autoantigen and its conserved homologs in mouse, fish, fly, and worm. World J Gastroenterol (2006) 0.78
Meta-analysis: diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a soluble liver antigen/liver pancreas in autoimmune hepatitis. PLoS One (2014) 0.78
The importance of autoantibody detection in autoimmune hepatitis. Front Immunol (2015) 0.78
Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. J Autoimmune Dis (2007) 0.78
Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis. Dig Dis Sci (2017) 0.77
Clinical features in different age groups of patients with autoimmune hepatitis. Exp Ther Med (2013) 0.77
Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. Gut Liver (2016) 0.77
Drug-induced hepatitis superimposed on the presence of anti-SLA antibody: a case report. J Med Case Rep (2008) 0.76
Association Between TT Virus Infection and Cirrhosis in Liver Transplant Patients. Hepat Mon (2015) 0.75
Prognostic Implications of Antibodies to Soluble Liver Antigen in Autoimmune Hepatitis: A PRISMA-Compliant Meta-Analysis. Medicine (Baltimore) (2015) 0.75
Requirements for Minimum Sample Size for Sensitivity and Specificity Analysis. J Clin Diagn Res (2016) 0.75
Diagnostic autoantibodies for autoimmune liver diseases. Clin Transl Immunology (2017) 0.75
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57
Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet (2000) 2.01
Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology (1988) 1.79
Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology (1993) 1.71
Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol (2000) 1.58
Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci U S A (1992) 1.58
Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet (1987) 1.43
Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology (1992) 1.32
Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology (1999) 1.25
Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. Clin Exp Immunol (2000) 1.07
The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am J Gastroenterol (1995) 1.05
Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol (1999) 1.04
The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology (1993) 1.04
Autoantibodies in liver disease. Gastroenterology (2001) 1.01
Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology (1993) 0.98
Primary and secondary liver/kidney microsomal autoantibody response following infection with hepatitis C virus. Gastroenterology (1994) 0.94
The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis. Gut (1998) 0.89
Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology (2001) 0.86
Heterogeneity of liver-kidney microsomal autoantibodies in chronic hepatitis C and D virus infection. Gastroenterology (1995) 0.85
Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis? J Hepatol (1998) 0.85
Relation between autoimmune liver diseases and viral hepatitis: clinical and serological characteristics in 859 patients. Z Gastroenterol (1995) 0.84
Glutathione S-transferase as a major autoantigen in anti-SLA-positive autoimmune hepatitis. Gastroenterology (1999) 0.84
Analysis of the hepatitis C virus genome in patients with anti-LKM-1 autoantibodies. J Hepatol (1994) 0.84
Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease -- possible association with a steroid-resistant transplant rejection episode. J Hepatol (1999) 0.83
Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology (1993) 0.83
Low hepatitis C viremia levels in patients with anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis. J Hepatol (1996) 0.81
Lessons about antibodies in autoimmune hepatitis. Lancet (2000) 0.81
Serological definition of new subgroup of patients with autoimmune chronic active hepatitis. Lancet (1987) 0.78
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med (1996) 5.09
The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med (2002) 4.47
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology (1999) 4.13
Randomized clinical trial on the effect of coffee on postoperative ileus following elective colectomy. Br J Surg (2012) 4.01
Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet (1998) 3.94
Physicians' attitudes about prescribing and knowledge of the costs of common medications. Arch Intern Med (2000) 3.17
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med (1998) 2.91
Antibody engineering for the analysis of affinity maturation of an anti-hapten response. EMBO J (1988) 2.81
Endoscopic lithotomy of common bile duct stones with sublingual nitroglycerin and guidewire. Am J Gastroenterol (1997) 2.62
Human Xq24-Xq28: approaches to mapping with yeast artificial chromosomes. Am J Hum Genet (1990) 2.45
Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest (1997) 2.32
Colonic toxicity of administered medications and chemicals. Am J Gastroenterol (1993) 2.31
In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy. Gut (2005) 2.30
Diversity of Helicobacter pylori vacA and cagA genes and relationship to VacA and CagA protein expression, cytotoxin production, and associated diseases. J Clin Microbiol (1998) 2.26
In vivo molecular imaging with cetuximab, an anti-EGFR antibody, for prediction of response in xenograft models of human colorectal cancer. Endoscopy (2013) 2.25
Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology (1995) 2.21
The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology (1989) 2.19
Body mass index in male patients with COPD: correlation with low attenuation areas on CT. Thorax (2008) 2.12
High definition colonoscopy combined with i-Scan is superior in the detection of colorectal neoplasias compared with standard video colonoscopy: a prospective randomized controlled trial. Endoscopy (2010) 2.01
Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet (2000) 2.01
Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J Clin Invest (1998) 1.86
Characterization of DNA polymerase from Pyrococcus sp. strain KOD1 and its application to PCR. Appl Environ Microbiol (1997) 1.86
In vivo diagnosis of collagenous colitis by confocal endomicroscopy. Gut (2006) 1.82
IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle (2005) 1.79
Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology (1993) 1.75
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J Immunol (1995) 1.72
High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology (1995) 1.70
TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol (1999) 1.69
An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol (1994) 1.68
Yeast artificial chromosomes with 200- to 800-kilobase inserts of human DNA containing HLA, V kappa, 5S, and Xq24-Xq28 sequences. Proc Natl Acad Sci U S A (1989) 1.66
Autoimmunity and liver disease. Hepatology (1990) 1.65
Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr (1990) 1.61
Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. Mayo Clin Proc (1993) 1.59
CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. AJR Am J Roentgenol (1997) 1.58
Detection of subclinical disorders of the hypopharynx and larynx by gastrointestinal endoscopy. Endoscopy (1996) 1.56
Methylene blue-aided cholangioscopy in patients with biliary strictures: feasibility and outcome analysis. Endoscopy (2008) 1.54
Induction of cytokine production in naive CD4(+) T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells. Gastroenterology (1999) 1.54
Papillary dilation vs sphincterotomy in endoscopic removal of bile duct stones. A randomized trial with manometric function. Dig Dis Sci (1995) 1.53
Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol (2001) 1.52
Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med (2001) 1.52
Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut (2011) 1.51
Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer (2006) 1.48
Autoimmune hepatitis in Brazilian patients is not linked to tumor necrosis factor alpha polymorphisms at position -308. J Hepatol (2001) 1.46
Recognition and characterization of small colonic neoplasia with high-definition colonoscopy using i-Scan is as precise as chromoendoscopy. Dig Liver Dis (2009) 1.46
Frequency and significance of antibodies to chromatin in autoimmune hepatitis type I. J Gastroenterol Hepatol (2000) 1.46
Animal models of non-alcoholic steatohepatitis: of mice and man. Dig Dis (2010) 1.45
A new treatment for severe malabsorption due to radiation enteritis. Lancet (1996) 1.45
Autoimmune hepatitis. N Engl J Med (1995) 1.45
MedJet--a new CO2-based disposable cleaning device allows safe and effective bowel cleansing during colonoscopy: a pilot study. Endoscopy (2012) 1.44
Increased p53 mutation load in nontumorous human liver of wilson disease and hemochromatosis: oxyradical overload diseases. Proc Natl Acad Sci U S A (2000) 1.44
Hormone replacement therapy: where we stand in Europe. Eur Heart J (2001) 1.44
Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation (2001) 1.44
Crystal structure of DNA polymerase from hyperthermophilic archaeon Pyrococcus kodakaraensis KOD1. J Mol Biol (2001) 1.43
Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nat Med (1998) 1.43
Serologic markers of hepatitis A and B in acute and chronic liver disease. Mayo Clin Proc (1979) 1.43
Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. Nat Med (1998) 1.42
Characterization of anti-histone antibodies in patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol (1998) 1.42
Successful and long-lasting treatment of solar urticaria with ultraviolet A rush hardening therapy. Br J Dermatol (2012) 1.42
Successful treatment of Erdheim-Chester disease with combination of interleukin-1-targeting drugs and high-dose glucocorticoids. Intern Med J (2014) 1.42
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst (1988) 1.41
Cure of gastric ulcer disease after cure of Helicobacter pylori infection--German Gastric Ulcer Study. Eur J Gastroenterol Hepatol (1996) 1.40
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol (1992) 1.40
Efficacy of transthoracic needle aspiration in community-acquired pneumonia. Intern Med (2001) 1.39
Role of energy metabolism in drug-induced acute gastric mucosal injuries in humans. J Gastroenterol Hepatol (2000) 1.37
Apoptosis and the liver. Semin Cancer Biol (2000) 1.37
Chrysotherapy. Suppression of immunoglobulin synthesis. Arthritis Rheum (1978) 1.36
Confocal laser endomicroscopy: technical status and current indications. Endoscopy (2006) 1.36
Uptake and intracellular distribution of silver nanoparticles in human mesenchymal stem cells. Acta Biomater (2010) 1.34
Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci (1998) 1.34
Serum antibodies against Helicobacter pylori proteins VacA and CagA are associated with increased risk for gastric adenocarcinoma. Dig Dis Sci (1997) 1.34
Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods (1996) 1.33
Myristylation of the large surface protein is required for hepatitis B virus in vitro infectivity. Virology (1996) 1.33
Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis. Oncogene (2001) 1.33
Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol (2000) 1.32
IL-10 down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells through decreased antigen uptake via the mannose receptor and lowered surface expression of accessory molecules. Clin Exp Immunol (1998) 1.32
Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology (1996) 1.30
Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology (1996) 1.29
Mouse models of liver fibrosis. Z Gastroenterol (2007) 1.29
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol (2010) 1.27
Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology (2000) 1.26
Recent trends in diverticulosis of the right colon in Japan: retrospective review in a regional hospital. Dis Colon Rectum (2000) 1.26
Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology (1999) 1.25
Minilaparoscopy in the diagnosis of cirrhosis: superiority in patients with Child-Pugh A and macronodular disease. Endoscopy (2003) 1.24
Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat (2001) 1.23